[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Cologne\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":561},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,40,75,101,128,153,179,203,218,244,266,290,315,338,359,383,407,437,458,482,502,520,539],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100054065","phase-2-a-multicenter-phase-ii-trial-to-evaluate-rechallenge-with-platinum-based-chemotherapy-carboplatin-etoposide-for-progression-during-tarlatamab-therapy-in-relapsed-extensive-disease-small-cell-lung-cancer-sclc-100054065",false,"NCT07699237","A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)","REPLAT- A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)","REPLAT","Inclusion Criteria:\n\n1. Capable of providing signed informed consent, which includes compliance with the requirements and restrictions outlined in the informed consent form (ICF) and this protocol. Written informed consent and any locally required authorization (e.g., European Union \\[EU\\] Data Privacy Directive) must be obtained from the patient\u002Flegal representative prior to performing any protocol-related procedures, including screening evaluations.\n2. Provision of signed and dated, written ICF prior to any mandatory study-specific procedures, sampling, and analyses.\n3. Age ≥ 18 years at the time of signing the informed consent.\n4. Willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits, examinations, and follow-up.\n5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n6. Patients must have a life expectancy of ≥ 12 weeks.\n7. Histologically or cytologically confirmed locally advanced or metastatic SCLC (UICC stage III not amenable to curative radiochemotherapy or stage IV). Note: Assignment of stage must be done according to the 9th edition of American Joint Committee on Cancer (AJCC)\u002FUnion for Interational Cancer Control (UICC) TNM staging system\n8. Disease progression or relapse after first-line platinum-based therapy with a platinum-free interval (PFI) ≥ 90 days (time between last platinum administration and first documented progression).\n\n   * Patients who received first-line systemic platinum-based chemotherapy for extensive stage (ES) disease are eligible.\n   * Patients must have failed or be ineligible for PD-L1 inhibitor therapy.\n   * Only one prior line of systemic chemotherapy is permitted. Patients who have previously been treated with chemotherapy as part of a limited stage (LS) disease may participate if there was a period of \\>6 months between the end of chemotherapy during the LS disease and chemotherapy as part of the ES disease.\n9. Radiological evidence of disease progression while on treatment with tarlatamab. Patients who show progression on tarlatamab in combination with a PD-L1 inhibitor may be included.\n10. Before starting study therapy (C1D1), a new biopsy of the tumor must be performed after progression under tarlatamab.\n\n    * Lesions that show progression under tarlatmab should be prioritized. Appropriate documentation (e.g., radiological report) must be available to demonstrate progress under Tarlatamab.\n    * Patients must be eligible for a biopsy of the tumor tissue in accordance with the guidelines of the treating institution.\n    * The tumor sample must be provided to the sponsor in accordance with the provisions of this protocol. The shipment should be made as soon as possible.\n    * If a tumor sample has already been taken after progression under tarlatmab for other reasons, the archived material can also be used for inclusion, and no new tumor biopsy is required for study inclusion.\n    * If a biopsy is not possible during tarlatamab treatment and no archived tumor sample is available after progression under tarlatamab, inclusion may be possible after discussion with the sponsor.\n11. Availability of a tumor sample obtained prior to the start of first-line treatment.\n\n    * The tumor sample must be provided to the sponsor in accordance with the provisions of this protocol. The tumor sample should have been sent to the sponsor prior to C1D1.\n    * If unavailable, inclusion may be possible after discussion with the sponsor.\n12. There must be a maximum of 28 days between the last dose of tarlatamab and the first dose of tarlatamab as part of the study treatment. Patients may receive tarlatamab beyond progression as standard therapy during the screening phase. If tarlatamab was last administered with a PD-L1 inhibitor, this therapy may be continued during screening as part of standard of care. No PD-L1 inhibitor may be administered after C1D1.\n13. Adequate tumor imaging (CT or MRI) within 28 days prior to enrollment. Imaging from the standard of care can be used for inclusion. For adequate imaging a slice thickness of 5 mm in CT and 5 mm in MRI with contrast agent should not be exceeded. More detailed information can be found in the Radiology Manual.\n14. Measurable disease as defined per RECIST 1.1 within the 28-day screening period.\n15. Adequate hematologic and organ function:\n\n    1. Haemoglobin ≥9 g\u002FdL\n    2. Absolute neutrophil count (ANC) ≥1.5 × 109 \u002FL\n    3. Platelet count ≥100 × 109\u002FL\n    4. Aspartate aminotransferase (AST) \u002F Alanine aminotransferase (ALT) ≤ 2.5 x institutional upper limit of normal unless liver metastases are present in which case they must be ≤ 5x ULN\n    5. Measured creatinine clearance \\>41 mL\u002Fmin or Calculated creatinine creatinine clearance \\>41 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance. Estimated creatinine clearance = (140-age \\[years\\]) x weight (kg) (x F) serum creatinine (mg\u002FdL) x 72 where F=0.85 for females and F=1 for males.\n16. Before enrollment, a woman must be either:\n\n    1. Not of childbearing potential: premenarchal; postmenopausal (for definition, see section 4.5)\n    2. Of childbearing potential: practicing effective method(s) of birth control consistent with local regulations regarding the use of birth control methods for patients participating in clinical studies (see section 4.5 and Annex 13.1)\n    3. Patients must agree to continue using contraception throughout the study and for 2 months after the last dose of tarlatamab and for 6 months after the last dose of carboplatin\u002Fetoposide. Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) the woman must begin a highly effective method of birth control, as described above.\n17. A woman of childbearing potential must have a negative serum (b-human chorionic gonadotropin \\[b-hCG\\]) at screening. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 2 months after the last dose of tarlatamab and 6 months after receiving the last dose of carboplation and\u002For etoposide .\n18. A man who is sexually active with a woman of childbearing potential must agree to use a condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository and his partner must also be practicing a highly effective method of contraception (see section 4.5). If the subject is vasectomized, he must still use a condom (with or without spermicide), but his female partner is not required to use contraception.\n\nThe subject must also not donate sperm during the study and for 2 months after the last dose of tarlatamab and 6 months after receiving the last dose of carboplatin and\u002For etoposide .\n\nExclusion Criteria:\n\n1. Symptomatic CNS metastases. Subjects with treated or untreated brain metastases are eligible provided the following criteria are met:\n\n   * Subject is asymptomatic from brain metastases. If, in the opinion of the investigator, asymptomatic, untreated brain metastases do not require local therapy, patients may be included.\n   * Whole brain radiation or surgery was completed at least 2 weeks prior to first dose of study treatment\n   * Stereotactic radiosurgery completed at least 7 days prior to first dose of study treatment\n   * Any CNS disease is clinically stable, subject is off steroids for CNS disease for at least 5 days (unless steroids are indicated for a reason unrelated to CNS disase), and subject is off or on stable doses of anti epileptic drugs at least 14 days prior to first dose of study treatment\n2. History of leptomeningeal carcinomatosis.\n3. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.\n4. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy. Exceptions are:\n\n   1. Alopecia (any Grade)\n   2. Vitiligo (any Grade)\n   3. Dysgeusia (any Grade)\n   4. Hypothyroidism stable on hormone replacement (Grade ≤2)\n   5. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the sponsor\n   6. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment may be included only after consultation with the sponsor.\n   7. For special requirements in the laboratory see Point 14 at inclusion criteria. Note: Grading of toxicities must be done according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.\n5. History of another primary malignancy in the past 2 years. Exceptions are:\n\n   1. Malignancy treated with curative intent and with no known active disease \\>1 years before the first dose of study treatment and of low potential risk for recurrence\n   2. Adequately treated non melanoma skin cancer or lentigo maligna without evidence of disease\n   3. Adequately treated carcinoma in situ without evidence of disease\n   4. Curatively treated localized prostate cancer receiving androgen deprivation therapy and considered to have a very low risk of recurrence\n   5. Lobular carcinoma in situ or ductal carcinoma in situ of the breast that is considered completely cured\n   6. Curatively treated in situ cancer of the cervix, ductal carcinoma in situ, Stage 1, grade 1 endometrial carcinoma\n   7. Curatively treated localized breast cancer receiving antihormonal agents and considered to have a very low risk of recurrence.\n6. Any acute, chronic or uncontrolled medical, mental or psychological condition, which in the opinion of the investigator would not permit the subject to participate in the study, complete the study or understand the patient information. These may include, but are not limited to:\n\n   1. Uncontrolled infection\n   2. Uncontrolled diabetes\n   3. Uncontrolled major seizure disorder\n   4. Superior vena cava syndrome\n   5. Active, chronic or ongoing infection requiring systemic anti-infective treatment (e.g.\n\n      tuberculosis). For a (HIV) and viral hepatitis, please see exclusion criteria below.\n   6. Intestitial lung disease\n   7. Psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n7. Patient has a history of clinically significant cardiovascular disease including, but not limited to the following:\n\n   1. Pericarditis\n   2. Recent (within 3 months) myocardial infarction\n   3. Symptomatic congestive heart failure\n   4. Uncontrolled hypertension\n   5. Unstable angina pectoris\n   6. Pericardial effusion (pericardial effusion considered due to the disease under study is permitted if clinically stable at screening)\n   7. Myocarditis that is clinically unstable\n   8. Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, electrolyte disturbances, etc.), or patients with congenital long QT syndrome. Every patient must have triple baseline ECG in the screening. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart)\n8. History of active primary immunodeficiency\n9. Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc) at screening. Participants with a past or resolved HBV infection (defined as the presence of anti-HBc and absence of HBsAg) are eligible.\n\n   Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n\n   \\- Participants co-infected with HBV and HCV, or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and\u002For anti HBcAb with detectable HBV DNA)\n\n   \\- HCV positive (presence of anti-HCV antibodies)\n10. Patient is known to be positive for HIV with 1 or more of the following:\n\n    * Not receiving highly active antiretroviral therapy (ART)\n    * Had a change in ART within 6 months of the start of screening\n    * Receiving ART that may interfere with study treatment\n    * CD4+ count \\\u003C350 \u002Fmm3 at screening\n    * AIDS-defining opportunistic infection within 6 months of start of screening\n    * Does not agree to start ART and be on ART \\>4 weeks plus having HIV viral load \\\u003C400 copies\u002FmL at end of 4-week period (to ensure ART is tolerated and HIV controlled).\n11. History of solid organ transplantation.\n12. Current or prior use of immunosuppressive medication within 7 days before the first dose of trial treatment. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n    * Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent\n    * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n    * Prophylaxis during therapy with tarlatamab\n    * Any anti-emetic\n13. Receipt of live attenuated vaccine within 14 days prior to the first dose of study medication. Inactive vaccines (eg, non-live or non-replicating agent) and live viral non-replicating vaccines (eg, Jynneos for Monkeypox infection) within 3 days prior to first dose of study treatment.\n14. Major surgery within 4 weeks of starting study treatment.\n\n    * Patients must have recovered from any effects of any major surgery or an anticipated need for major surgery during the study.\n    * Local surgery of isolated lesions for palliative intent is acceptable, as long as this does not affect the only target lesion.\n15. Any herbal or prescription\u002Fnon-prescription medications known to inhibit membrane transporters Pglycoprotein (P-gp) and\u002For breast cancer resistance protein (BCRP) (including but not limited to cyclosporine, clarithromycin, itraconazol, or ketoconazole) within 7 days prior to the first dose of study treatment\n16. Any herbal or prescription\u002Fnon-prescription medications known to be moderate or strong inhibitors of cytochrome P450 3A (CYP3A) enzymes (including but not limited to clarithromycin, itraconazole, ketoconazole) within 7 days prior to the first dose of study treatment.\n17. Any herbal or prescription\u002Fnon-prescription medications known to be moderate or strong inducers of CYP3A enzymes (including but not limited to efavirenz, penobarbital, phenytoin, rifampin, St John's Wort) within 28 days prior to first odse of study treatment.\n18. Treatment with live virus, including live-attenuated vaccination, within 14 days prior to the first dose of study treatment. Inactive vaccines (eg, non-live or non-replicating agent) and live viral nonreplicating vaccines (eg Jynneos for Monkeypox infection) within 3 days prior to first dose of study treatment.","ALL","18 Years",{"count":20,"type":21},54,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The integration of tarlatamab, a bispecific T-cell engager molecule targeting both DLL3 and CD3, into the treatment algorithm for SCLC will substantially improve the prognosis of patients. Nevertheless, disease progression will inevitably occur.\n\nMajor challenges for further improving tarlatamab therapy are the molecular understanding of resistance to tarlatamab and the selection of the optimal systemic therapy upon progression. Patients who experience platinum-sensitive progression more than 90 days after first-line chemoimmunotherapy (platinum-free interval (PFI) = day of last administration of platinum-containing chemotherapy until progression) and subsequently progress on tarlatamab therapy may benefit from a platinum-based chemotherapy re-challenge while remaining on tarlatamab treatment. We hypothesize that patients who progress while on tarlatamab may benefit more from the combination of both therapies than from sequential therapy due to synergistic effects. We assume that, besides the cytotoxic effects of platinumbased chemotherapy, additional T-cell modifying effects could support this concept. The disruption of the tumor stroma, which has been described in various chemotherapies, could increase T-cell infiltration and thus have additional immunostimulatory effects (Hoff et al., 2011). The lymphodepletion triggered by chemotherapy and the resulting release of interleukins such as IL-15 could also have an enhancing effect on therapy with bispecific T-cell engagers (Kochenderfer et al., 2017). In addition, it has been shown preclinically that chemotherapeutic agents that have an inhibitory effect on topoisomerase (e.g. doxorubicin) also have a selective inhibitory effect on MDSCs. Here, the administration of the topoisomerase inhibitor etoposide could counteract possible resistance mechanisms (Alizadeh et al., 2014). Different cut-off values for chemotherapy-sensitive progression in small cell lung cancer between 60 - 90 days PFI have been discussed for decades. It has been shown that a platinum re-challenge as a second chemotherapy regimen is superior in a patient population with a PFI greater than 90 days compared to topotecan (Baize et al., 2020). This is expected to apply to approximately 40% of patients receiving standard first-line platinum-based therapy with PD-L1 inhibitors (Torsawa et al., 2023). If tarlatamab is added to first-line therapy in the near future, the proportion of patients with a PFI of more than 90 days could increase further. In the future, platinum-containing chemotherapy could become an increasingly important role as second-line chemotherapy. In parallel with the clinical evaluation of the re-challenge concept, we will conduct an extensive rebiopsy program. This will include a re-biopsy during progression to tarlatamab therapy at screening and a re-biopsy at the time of progression to the study treatment. Whole exome sequencing and transcriptomic analyses of tumor bulks as well as transcriptomic analysis at the single-cell level will be performed to elucidate molecular mechanisms of resistance in the tumor cells and in the tumor microenvironment. Additional immunohistochemical",[27],"Extensive Disease Small Cell Lung Cancer","NOT_YET_RECRUITING","2026-07-07",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":21},"2026-11-01",{"date":36,"type":21},"2031-06-30",{"name":38,"class":39},"University of Cologne","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100614514","phase-3-stop-pkd-sglt2-inhibition-to-improve-prognosis-in-polycystic-kidney-disease-100614514","NCT07280585","STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease","STOP-PKD","Inclusion Criteria:\n\n* Male and female patients with ADPKD (modified Ravine criteria) ≥ 18 and ≤ 60 years\n* Patients 18 - 39 years: eGFR ≥25 ml\u002Fmin; patients 40 - 60 years: eGFR ≥25 and \\\u003C90 ml\u002Fmin\u002F1.73 m2\n* Indicators of rapid progression, either of the following:\n* Mayo class 1D-E\n* Mayo class 1C AND EITHER\n\n  1. Truncating PKD1 mutation OR\n  2. eGFR loss \\> 3ml\u002Fmin\u002Fyear (determined by ≥ 4 creatinine values within 4 years, ≥ 6 months measurement intervals) OR\n  3. PROPKD score \\> 6 (patient history)\n* IF patient is on ACE-I \u002FARBs: stable dose for 4 weeks before screening\n\nExclusion Criteria:\n\n* Treatment with tolvaptan, somatostatin analogue, lithium or SGLT2i within the last 3 months before screening\n* Medical history of diabetic ketoacidosis, necrotizing fasciitis or organ transplantation\n* Diabetes mellitus type 1 or any type of diabetes mellitus due to insulin deficiency\n* Uncontrolled ongoing urinary tract or genital infections\n* Known intolerance of the study medication ingredients\n* Uncontrolled grade 2 hypertension (\\>160\u002F100 mmHg)\n* Symptomatic hypotension, or systolic blood pressure \\\u003C90 mmHg\n* Primary renal disease other than ADPKD\n* Hepatic impairment (aspartate transaminase \\[AST\\] or alanine transaminase \\[ALT\\]\\>3x the up-per limit of normal \\[ULN\\]; or total bilirubin \\>2x ULN at time of enrolment)\n* Pregnancy, breastfeeding or women of child-bearing potential not using effective contraception method\n* Not able to comply with the study protocol, in the investigator's judgement\n* Not able to provide informed consent\n* Participation in any other interventional clinical trial in the last 2 months","60 Years",{"count":49,"type":21},420,[51],"PHASE3","Autosomal dominant polycystic kidney disease is the most common genetic cause of kidney failure. The only approved treatment for ADPKD - tolvaptan - is limited in its use by massive therapy-associated polyuria. This trial tests if the SGLT2-inhibitor dapagliflozin slows down the loss of kidney function in ADPKD.",[54],"Polycystic Kidney, Autosomal Dominant",[45,56,57,58,59,60,61,62,63,64],"ADPKD","Dapagliflozin","SGLT2","PKD","polycystic kidney disease","SGLT2i","sodium-glucose","sodium glucose","Phase 3","RECRUITING","2026-06-12",{"date":68,"type":32},"2026-06-15",{"date":70,"type":32},"2025-12-16",{"date":72,"type":21},"2030-05-15",{"name":38,"class":39},30,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},"100563157","vaccine-induced-immunity-in-immunocompromised-patients-100563157","NCT06612515","Vaccine-induced Immunity in Immunocompromised Patients","Prospective Cohort-study for the Investigation of the Vac-cine-induced Immune Response After Vaccination Against RESPiratory Viral Infections in Immunocompromised Pa-tients With or Without Haemato-ONcological diseaSEs","RESPONSE","Inclusion Criteria:\n\n* Signed informed consent form\n* Patients with immunosuppression either by treatment or underlying diseases\n* Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations\n* Age of 18 years or older\n\nExclusion Criteria:\n\n* Patients unwilling\u002Fineligible for vaccination under current recommendations",true,{"count":85,"type":21},1000,"OBSERVATIONAL","Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals.\n\nIn hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.",[89],"Immunodeficiency",[91],"vaccine; Immunocompromised; immune response","2026-05-11",{"date":94,"type":32},"2026-05-12",{"date":96,"type":32},"2025-03-25",{"date":98,"type":21},"2029-12-31",{"name":38,"class":39},1,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":100},"100493780","dietary-interventions-during-living-kidney-donations-100493780","NCT05709600","Dietary Interventions During Living Kidney Donations","Dietary Interventions During Living Kidney Donations (DILKID Trial)","DILKID","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Planed living kidney transplantation (both donor and recipient are eligible)\n* Written informed consent\n\nExclusion Criteria:\n\n* Vegetarian lifestyle\n* Body-Mass-Index (BMI) \\\u003C 18.5 kg\u002Fm2\n* Calorie-reduced diet within the preceding four weeks\n* Underlying wasting syndrome\n* Contraindication for enteral nutrition\n* Known allergy to or intolerance of the ingredients of the diet used\n* Pregnancy\n* Breastfeeding\n* Absence of safe contraceptive measures or non-occurrence of menopause (in women)\n* Participation in other interventional trials",{"count":110,"type":21},80,[112],"NA","Monocentre, non-randomized, non-blinded, open-label interventional study to identification of relevant changes in molecular biology in proteome, phosphoproteome, lipidome, epigenome and transcriptome in pretransplant kidney biopsy samples in patients preconditioned by different dietary regimes (fasting mimicking diet vs. ketogenic diet vs. dietary restriction of sulfur containing amino acids vs. control patients)",[115],"Living-Kidney Donors",[117,118,119],"Transplant","Acute Kidney Injury","Kidney Dietary Interventions","2026-04-29",{"date":122,"type":32},"2026-04-30",{"date":124,"type":32},"2023-02-01",{"date":126,"type":21},"2027-06-30",{"name":38,"class":39},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":138,"studyType":86,"phases":4,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100247281","the-german-adpkd-tolvaptan-treatment-registry-100247281","NCT02497521","The German ADPKD Tolvaptan Treatment Registry","The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.","AD(H)PKD","Inclusion Criteria:\n\n* Age \\> 18 years\n* ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician\n* Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started\n\nExclusion Criteria:\n\n* Patients not capable of giving informed consent\n* End stage renal disease requiring renal replacement therapy\n* Patients receiving tolvaptan as \"off-label use\"",{"count":137,"type":21},2000,"10 Years","The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide \"real-world\" data on treatment management of patients with ADPKD.",[141],"ADPKD (Autosomal Dominant Polycystic Kidney Disease)",[60,143,56,144,145],"autosomal dominant polycystic kidney disease","Tolvaptan","Jinarc",{"date":122,"type":32},{"date":148,"type":32},"2015-11",{"date":150,"type":21},"2027-12",{"name":38,"class":39},12,{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":162,"briefSummary":163,"conditions":164,"keywords":168,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":100},"100514185","continuous-delivery-room-skin-to-skin-study-for-moderate-and-late-preterm-infants-100514185","NCT05975203","Continuous Delivery Room Skin-to-skin-study for Moderate and Late Preterm Infants","COSY","Inclusion Criteria:\n\n* preterm birth between gestational age of 32 0\u002F7 and 36 6\u002F7 weeks\n* vaginal delivery\n* singleton\n* informed consent before birth\n\nExclusion Criteria:\n\n* malformations or syndromes of the infant\n* resuscitation of the infant\n* maternal psychological or severe physical illness\n* lack of German language skills",{"count":161,"type":21},60,[112],"The goal of this randomized controlled trial is to compare the effect of direct skin-to-skin contact in moderate and late preterm infants. The main questions it aims to answer are:\n\n* does skin-to-skin contact in moderate and late preterm infants influence gene expression in the stress signaling pathway?\n* does skin-to-skin contact in moderate and late preterm infants improve the short- and long-term outcome?\n\nParticipants will either get immediate separation after vaginal birth or receive immediate skin-to-skin contact. Researchers will compare these two groups to answer the proposed questions.",[165,166,167],"Preterm Birth","Mother-Infant Interaction","Infant Development",[169,170],"preterm behavioral epigenetics","skin-to-skin contact","2026-02-18",{"date":173,"type":32},"2026-02-20",{"date":175,"type":32},"2023-08-04",{"date":177,"type":21},"2028-12-31",{"name":38,"class":39},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":185,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":100},"100387374","hantavirus-registry---hantareg-100387374","NCT04323904","Hantavirus Registry - HantaReg","Hantavirus Registry Gathers Knowledge on Epidemiology, Clinical Course, Prognostic Factors and Molecular Characteristics for Hantavirus Infections and Their Complications (HantaReg)","HantaReg","Inclusion Criteria:\n\n* Serological or molecular evidence of hantavirus infection and clinical evidence of nephropathia epidemica or hemorrhagic fever with renal syndrome (HFRS)\n* Serological or molecular evidence of hantavirus infection and clinical evidence of hantavirus cardiopulmonary syndrome (HCPS)\n\nExclusion Criteria:\n\n\\- Serological or molecular evidence of hantavirus infection without clinical signs of nephropathia epidemica, HFRS or HCPS",{"count":188,"type":21},200,"Hantavirus disease are zoonotic infections and remain a clinical challenge with globally increasing incidence and multiple serious outbreak situations in Europe within the last years. Hantavirus disease encompasses two clinical syndromes, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS) caused by Old World and New World hantaviruses, respectively. Depending on the causative Old World hantavirus species, clinical course of HFRS can vary from mild to moderate to severe.\n\nAt present, there is no specific therapy available for hantavirus disease. As the clinical course of hantavirus disease is dependent on the causing viral pathogen and as there worrisome hints that clinical course HFRS and HCPS overlap, further studies with regard to the disease course are mandatory. Furthermore, the examination of attributable mortality and costs of hantavirus disease will need to be studied on a multinational basis and therefore HantaReg will particularly use a matched case control design.",[191,192,193,194],"Hantavirus Infections","Hemorrhagic Fever With Renal Syndrome","Nephropathia Epidemica","Hantavirus Cardiopulmonary Syndrome","2025-12-09",{"date":197,"type":32},"2025-12-17",{"date":199,"type":32},"2020-03-04",{"date":201,"type":21},"2030-12",{"name":38,"class":39},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":214,"startDateStruct":215,"completionDateStruct":216,"leadSponsor":217,"locationsCount":100},"100384666","leptospirosis-registry---leptoscope-100384666","NCT04288674","Leptospirosis Registry - LeptoScope","Leptoscope","Inclusion Criteria:\n\n* Cultural, serological, molecular or histological evidence of invasive leptospirosis diseases\n* Clinical signs of disseminated leptospirosis disease without cultural, serological, molecular or histological evidence\n* Case controls: Matching procedures for controls: Particularly, case controls will be included at the same hospitals that conduced cases based on matching of demographics, underlying diseases and duration of hospitalization (i.e. one control per case, both in the same hospital).\n\nExclusion Criteria:\n\n* Colonization or other non-invasive infection\n* Cultural, serological, molecular or histological evidence without dissemination",{"count":188,"type":21},"Leptospirosis is a worldwide zoonotic diseases caused by pathogenic Leptospira spp. Human are accidental hosts, who acquired infections after exposition to animal urine, contaminated water or soil, infected tissue. Incidence of invasive leptospirosis disease causing acute kidney injury, acute respiratory distress syndrome (ARDS), myocarditis, hepatic dysfunction, hemorrhage and multi-organ failure, is globally increasing and there have been frequent outbreak situation throughout the world. Due to increasing outbreak situations and globally chances in species distributions, a worldwide surveillance in epidemiology and species distribution is urgently needed. The objective of the Leptospirosis Registry - LeptoScope is to overcome the lack knowledge on epidemiology, clinical course, prognostic factors and molecular characteristics for invasive leptospirosis disease.",[213],"Leptospirosis",{"date":197,"type":32},{"date":199,"type":32},{"date":201,"type":21},{"name":38,"class":39},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":100},"100547446","regulation-of-extracellular-sodium-in-end-stage-renal-disease-upon-volume-and-electrolyte-challenges-100547446","NCT06408077","Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges","Regulation of Extracellular Sodium in End Stage Renal Disease Upon Volume and Electrolyte Challenges - a Prospective Trial.","RESERVE","Inclusion Criteria:\n\n* Adult patients ≥18 years\n* Requirement of renal replacement therapy due to surgical (i.e., nephrectomy) or non-surgical (chronic kidney disease) reason\n* Stable hemodialysis treatment for at least 3 months\n* Urine output \\\u003C100ml in 24 hours\n* Glucose-corrected plasma sodium between 135 mmol\u002Fl and 145 mmol\u002Fl\n* Plasma potassium between 3.5 mmol\u002Fl and 5 mmol\u002Fl\n* Written informed consent\n\nExclusion Criteria:\n\n* Peritoneal dialysis patients\n* Signs of volume expansion or contraction\n* Congestive heart failure (NYHA ≥2)\n* acute illness (infection, congestive heart failure, liver cirrhosis, etc.) requiring hospital admission\n* Uncontrolled arterial hypertension\n* Hemoglobin ≤8g\u002FdL\n* Alcohol abuse\n* Malnutrition\n* Persons, who are in a dependency\u002Femployment relationship with the investigators\n* Accommodation in an institution by judicial or administrative order",{"count":161,"type":21},[112],"Hyponatremia is the most common electrolyte disorder of all and can be observed in more than 30% of all patients in hospitals. Osmotic homeostasis of body fluids is essential for survival of all living creatures. It is widely accepted that extra- and intracellular osmolalities are in equilibrium at all times and thus, changes in the extracellular osmolality will lead to either shrinkage or swelling of cells which can be detrimental. In severe cases, it can lead to swelling of the brain and death. Even in less dramatic scenarios, symptoms such as epileptic seizures, headaches, depression and dizziness exist, leading to an increased risk of fractures, hospital admissions and a considerable burden for affected patients.\n\nAs short-term defense against osmotic stress, each individual cell is capable of actively externalizing or internalizing osmotically active solutes which restores normal or near-normal cell volume at the expense of an altered milieu interior. Obviously, there must be limitations to this strategy if intracellular integrity is meant to be kept stable. It has therefore been postulated that, apart from this cell-immanent mechanism, extracellular and intracellular electrolyte stores could assist in buffering osmotic imbalances.\n\nThe Edelman formula states that extracellular sodium is determined by the total amount of exchangeable body sodium (the major extracellular cation) plus potassium (the major intracellular cation) divided by total body water. Several studies have shown, that it only partially explains the changes in patients outside the osmotic equilibrium.\n\nTo better understand these physiological responses might not only promote the researcher's insight into the most basic cellular self-defense systems by measuring and comparing extra- and intracellular electrolyte concentrations with estimated changes in a patient that will be intravenously challenged with either water or sodium chloride 3%.\n\nThe evolution over time of extra- and intracellular sodium and other electrolytes will be assessed quantitatively in patients with impaired renal function after water or sodium chloride (NaCl) administration.",[230],"Hyponatremia",[232,233,234,235],"hyponatremia","prospective trial","intracellular measurements","Water-Electrolyte Imbalance","2025-09-10",{"date":238,"type":32},"2025-09-17",{"date":240,"type":32},"2023-07-01",{"date":242,"type":21},"2026-05-31",{"name":38,"class":39},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":100},"100492483","evaluation-of-volume-and-electrolyte-balance-in-hyponatremia-treatment---a-prospective-observational-trial-100492483","NCT05692726","Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial","Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial (EvenT)","EvenT","Inclusion Criteria:\n\n* Adult patients ≥ 18 years\n* Hypotonic hyponatremia\n\n  * glucose-corrected plasma sodium \\\u003C130 mmol\u002Fl\n  * serum osmolality \\\u003C280 mosmol\u002Fkg or lack of signs of non-hypotonic hyponatremia\n\nExclusion Criteria:\n\n* Signs of extracellular volume expansion\n* Patients with liver cirrhosis and severe liver damage AST\u002FALT\\>3xULN, AP\\>6xULN, Bilirubin ≥ 3mg\u002Fdl\n* Patients with heart failure\n* Patients on dialysis and\u002For patients with oliguric renal impairment and plasma creatinine ≥ 3mg\u002Fdl\n* Patients after organ transplantation",{"count":253,"type":21},50,"To assess quantitatively the evolution over time of electrolyte-free water clearance and electrolyte mass balance in patients with non-hypervolemic hypotonic hyponatremia",[256],"Non-hypervolemic Hyponatremia",[258,232],"Electrolyte-free water clearance",{"date":260,"type":32},"2025-09-11",{"date":262,"type":32},"2022-10-15",{"date":264,"type":21},"2026-09-30",{"name":38,"class":39},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":22,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":289},"100484056","phase-2-methotrexate-tafasitamab-lenalidomide-and-rituximab-in-patients-with-pcnsl-100484056","NCT05583071","Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL","Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in Patients Ineligible for HCT-ASCT With Primary Central Nervous System Lymphoma (PCNSL)","MTR²","Inclusion Criteria:\n\n1. Age 18-69 years with ECOG PS ≥2 or age ≥70 years, and ineligible for HCT-ASCT as per investigators discretion\n2. Previously untreated, histologically (or cytologically) confirmed diagnosis of primary B-cell lymphoma of the central nervous system (PCNSL) by local pathologist. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy\n3. At least one measurable lesion\n4. Adequate organ function:\n\n   * Adequate kidney function, defined as:\n\n     * Serum creatinine estimated glomerular filtration rate (MDRD) ≥ 50 ml\u002Fmin\n   * Adequate hepatic function, defined as:\n\n     * ALAT and ASAT ≤ 3 ULN\n     * Bilirubin ≤ 2.0 mg\u002Fdl (except for Meulengracht disease)\n   * Adequate bone marrow function, defined as:\n\n     * White blood cell (WBC) count ≥ 3000\u002FµL or absolute neutrophil count (ANC) ≥ 1000\u002FµL\n     * Platelets ≥ 50.000\u002FµL\n     * Hemoglobin \\> 8.0 g\u002Fdl\n   * Adequate cardiac function, defined as:\n\n     * Cardiac ejection fraction ≥ 40%\n   * Adequate pulmonary function as per investigators discretion\n5. Written, signed, and dated informed consent for the trial provided by the participant\n6. Female persons are eligible to participate if they are post-menopausal or females of no childbearing potential or if they agree to use a method of contraception considered safe described in Section 12.1.2.1.\n7. Male persons with female partners of childbearing potential are eligible to participate if they agree to contraceptive methods as described in Section 12.1.2.2.\n\nExclusion Criteria:\n\n1. Prior treatment for PCNSL with the exception of a pre-phase treatment comprising steroid treatment and \u002F or single application of rituximab 375 mg\u002Fm² and methotrexate 3.5 g\u002Fm²\n2. Systemic lymphoma manifestation outside the CNS\n3. Diagnosis of previous Non-Hodgkin lymphoma at any time\n4. Primary vitreoretinal or leptomeningeal lymphoma without manifestation in the brain parenchyma or spinal cord\n5. HIV infection of any stage as determined by presence of anti-HIV antibodies (confirmatory test) and \u002F or presence of RNA confirmed by PCR\n6. Previous or concurrent malignancies with the following exceptions:\n\n   * Surgically cured carcinoma in-situ\n   * Other kinds of cancer without evidence of disease for at least 5 years\n7. Hypersensitivity to study treatment or any component of the formulation\n8. Stomatitis or gastrointestinal ulcerations preventing the use of methotrexate\n9. Hepatitis B, hepatitis C or hepatitis E infection as determined by PCR\n10. Severe active infection\n11. Congenital or acquired immunodeficiency including previous organ transplantation\n12. Pregnant or nursing (lactating) women.\n13. Lack of accountability and inability to appreciate the nature, meaning and consequences of the trial and to formulate their own wishes correspondingly\n14. Non-compliance, for reasons including, but not limited to the following:\n\n    1. Increased alcohol consumption, drug dependency or substance abuse that would interfere with cooperation with requirements of the trial\n    2. Refusal of blood products during treatment\n    3. Any similar circumstances that appear to make protocol treatment or long-term follow-up impossible\n15. Relationship of dependence or employer-employee relationship to the sponsor or the investigator","99 Years",{"count":276,"type":21},20,[24],"Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)",[280],"Non-Hodgkin Lymphoma","2025-08-07",{"date":283,"type":32},"2025-08-13",{"date":285,"type":32},"2024-08-23",{"date":287,"type":21},"2027-04",{"name":38,"class":39},6,{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":4},"100586769","phase-2-phase-ii-trial-of-brecadd-in-hiv-positive-patients-with-advanced-stage-classical-hodgkin-lymphoma-100586769","NCT06919679","Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma","BASTION","Inclusion Criteria:\n\n* Histologically confirmed first diagnosis of cHL\n* Advanced-stage disease: stage IIB with large mediastinal mass and\u002For extranodal lesions or stage III or IV\n* No previous treatment for HL with the exception of steroid prephase\n* Confirmed HIV infection with CD4 counts ≥ 150\u002FμL at registration or \\> 250\u002FμL at any time within 8 months prior to HL diagnosis\n* Continuation of antiretroviral treatment (ART) \u002F Initiation of ART in patients who are ART-naive\n* Age: 18-60 years\n\nExclusion Criteria:\n\n* Previous malignancy during last 5 years or active malignancy, prior chemotherapy or radiotherapy which precludes protocol treatment\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Multi-drug resistant HIV infection or concurrent AIDS-defining conditions\n* Pregnancy or breastfeeding",{"count":298,"type":21},35,[24],"Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET\u002FCT) in order to guide response-adapted continuation of therapy consisting of 4 or only 2 additional cycles of BrECADD in case of a PET-positive or -negative staging result, respectively. A second restaging will be performed after completion of chemotherapy. In patients with PET-positive residual disease, local irradiation followed by another restaging is recommended. ART should be continued during chemotherapy.",[302],"Hodgkin Lymphoma (Category)",[304,305,306],"advanced stage","HIV positive","Brentuximab Vedotin","2025-04-02",{"date":309,"type":32},"2025-04-09",{"date":311,"type":21},"2025-08",{"date":313,"type":21},"2030-01",{"name":38,"class":39},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":335,"leadSponsor":337,"locationsCount":100},"100519564","phase-2-pembrolizumab-in-first-line-treatment-of-advanced-stage-classical-hodgkin-lymphoma-100519564","NCT06045195","Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma","Phase II Trial of Pembrolizumab in First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma","Pembro-FLASH","Main Inclusion Criteria:\n\n* age 18-60\n* advanced stage classical Hodgkin Lymphoma\n* no previous treatment for cHL\n\nMain Exclusion Criteria:\n\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma\n* Chemotherapy or radiotherapy in medical history\n* Prior or concurrent disease that prevents treatment according to protocol",{"count":324,"type":21},40,[24],"The primary objective of this trial is to estimate efficacy of the novel regimen. The primary endpoint is the 1-year PFS rate after treatment with one dose of pembrolizumab followed by four to six cycles of chemo-immunotherapy with P-BrECADD, and PET-guided radiotherapy as per standard of care",[328],"Hodgkin Lymphoma",[304,330,331],"first line treatment","PD-1 inhibitor",{"date":333,"type":32},"2025-04-06",{"date":311,"type":21},{"date":336,"type":21},"2029-01",{"name":38,"class":39},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":347,"briefSummary":348,"conditions":349,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":4},"100586518","phase-2-phase-ii-trial-of-anti-pd-1-antibody-treatment-and-radiotherapy-in-early-stage-favorable-classic-hodgkin-lymphoma-100586518","NCT06916416","Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma","PREFer","Inclusion Criteria:\n\n* Histologically proven first diagnosis of cHL\n* Stage I-II without risk factors\n\n  * Large mediastinal mass\n  * Extranodal involvement\n  * Elevated erythrocyte sedimentation rate (ESR)\n  * Involvement of ≥ 3 nodal areas\n\nExclusion Criteria:\n\n* Central nervous system lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma,\n* Prior cHL-directed treatment\n* Prior chemotherapy, RT or allogeneic stem cell\u002Fsolid organ transplant\n* Prior or concurrent disease precluding protocol treatment (for details see section 4.2)\n* Pregnancy or breastfeeding\n* Non-compliance","75 Years",{"count":253,"type":21},[24],"By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed early-stage favorable cHL.",[350],"Classical Hodgkin Lymphoma","2025-03-31",{"date":353,"type":32},"2025-04-08",{"date":355,"type":21},"2025-06",{"date":357,"type":21},"2028-06",{"name":38,"class":39},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":380,"leadSponsor":382,"locationsCount":100},"100547911","modulated-mid-frequency-whole-body-electromyostimulation-and-nutritional-therapy-in-gastrointestinal-cancer-patients-100547911","NCT06414122","Modulated Mid-frequency Whole-body Electromyostimulation and Nutritional Therapy in Gastrointestinal Cancer Patients","The Efficacy of Modulated Mid-frequency (Whole-body Electromyostimulation) and Nutritional Therapy in Patients With Solid Tumors of the Gastrointestinal Tract (Excluding Liver and Pancreatic Carcinomas)","MOMENT","Inclusion Criteria:\n\n* Patients with oesophageal, gastric, duodenal, colon or rectal cancer following surgery without further therapy and with neoadjuvant and adjuvant therapy\n* medical clearance for exercise training\n* written declaration of consent from the study participant\n\nExclusion Criteria:\n\n* Participation in another study on the topic of exercise or nutrition\n* Electronic implants such as pacemakers, pumps, and coronary stents\n* Cardiac arrhythmia\n* Implants in the area of application (e.g. breast implants)\n* Pregnancy\n* Epilepsy\n* Wounds and open skin diseases in the area of application of the electrodes\n* Unhealed operations or bone fractures\n* Acute inflammatory diseases (e.g. inflammation of the intervertebral discs, bones, vessels, or soft tissue)\n* Directly after herniated discs or other instabilities such as large abdominal wall hernias\n* Blood clots (thromboses)\n* Bone diseases with high-grade osteoporosis\n* Increased risk of haemorrhage\n* Fever and illnesses that can be aggravated by physical exertion\n* Untreated high blood pressure\n* Blindness\n* Continuous parenteral nutrition\n* Metal and electronic parts in the body (e.g. prostheses, metal vascular clips, hearing aids\u002Finner ear\u002Fcochlear implants, magnetic dental prostheses, pacemakers, contraceptives)",{"count":368,"type":21},88,[112],"The purpose of this study is to assess the efficacy of modulated mid-frequency whole-body electromyostimulation (WB-EMS) combined with nutritional therapy in patients with gastrointestinal cancer.",[372,373,374,375],"Oesophageal Cancer","Gastric Cancer","Duodenal Cancer","Colorectal Cancer","2025-03-14",{"date":378,"type":32},"2025-03-19",{"date":355,"type":21},{"date":381,"type":21},"2026-09",{"name":38,"class":39},{"id":384,"slug":385,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":387,"acronym":388,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":392,"conditions":393,"keywords":395,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":289},"100583362","a-multicentric-cohort-and-biomarker-study-for-improved-care-of-patients-with-extrapulmonary-tuberculosis-100583362","NCT06875336","A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis","mEX-TB","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Isolation of Mycobacterium tuberculosis complex from a bodily secretion or tissue by\n\n   1. PCR\n   2. culture or a presumptive clinical diagnosis based on epidemiologic exposure in combination with physical findings, radiographic findings and\u002For histopathology\n3. Patients with extrapulmonary TB\n\n   * pleura\n   * lymph nodes\n   * bones and joints\n   * larynx\n   * pericardial\n   * parotid gland\n   * abdominal sites\n   * kidneys\n   * genitourinary tract\n   * disseminated (miliary) TB\n   * other than pulmonary TB\n4. In the case of pulmonary and extrapulmonary involvement, the leading manifestation, clinically and radiographically, must be extrapulmonary.\n5. Written informed consent provided prior to inclusion\n\nExclusion Criteria:\n\n* 1\\. Age \\\u003C18 years 2. Patient with any social or logistical condition which, as anticipated by the investigator, may interfere with the conduct of the study, such as incapacity to well understand the study content and procedure (in case of any language barriers, a translator may be involved), not willing to collaborate, or anticipated inability to finish study due to physical weakness 3. Dependencies towards the study team (e.g. family members, employees of the same department) 4. Pregnant women 5. Patient in custodianship or guardianship 6. Leading pulmonary manifestation 7. Solitary CNS tuberculosis Patients may take part in other clinical studies and trials, as long as there is no conflict with the inclusion or exclusion criteria of the mEX-TB study and the protocol of the other study or trial does not conflict with the means of data and sample collection and publication of this protocol.",{"count":391,"type":21},150,"This is a prospective, multicenter, observational study (mEX-TB study) of patients with extrapulmonary tuberculosis (EPTB). Adult patients newly diagnosed with EPTB will prospectively be enrolled into the study. Clinical data will be collected using standardized questionnaires over the whole treatment period for each individual. Additionally, body fluids (blood, urine) will be collected and stored in a central biobank. Biomarkers in EPTB patients will be analyzed during the course of therapy and correlated with clinical data. In addition, a healthy control group will be added, to be used primarily as technical controls for complex laboratory procedures such as RNA-seq and T-cell based assays.",[394],"Extrapulmonary Tuberculosis",[396,397,398],"extrapulmonary tuberculosis","biomarker","cohort study","2025-03-07",{"date":401,"type":32},"2025-03-13",{"date":403,"type":32},"2023-03-06",{"date":405,"type":21},"2025-12-31",{"name":38,"class":39},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":413,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":422,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":436},"100548797","trial-comparing-cataract-surgery-with-triple-dmek-in-patients-with-cataract-and-fuchs-endothelial-corneal-dystrophy-100548797","NCT06425666","Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy","European Prospective Multicentre Trial Comparing Cataract Surgery With Triple-DMEK in Patients With Cataract and Fuchs Endothelial Corneal Dystrophy (ETCF-trial)","ETCF","Inclusion Criteria:\n\n1. Patients with FECD and nuclear cataract in study eye\n2. Male and female patients ≥18 years of age\n3. Subject must be able to understand and read the national language.\n4. Written informed consent prior to any study-related procedures\n5. Nuclear opalescence (NO) grades 2 and 3 according to the lens opacities classification system III (LOCS III)\n6. Krachmer grade (3 \\[2-5 mm diameter area with confluent guttae\\]; 4 \\[ \\> 5 mm diameter area with confluent guttae\\] without edema identified by slit lamp examination)\n7. Central corneal thickness (CCT) measured with Pentacam below 620 µm between 8:00 am and 01:00 pm\n8. BCVA logMAR \\\u003C 0,7 and \\> 0,1\n9. No previous cataract surgery or triple-DMEK on the opposite side\n10. Pentacam quality specification: \"OK\"\n11. For women below age of 60 negative urine pregnancy test\n\nExclusion Criteria:\n\n1. Patients with ocular and\u002For systemic comorbidity affecting vision or clinically proven anterior and\u002For posterior segment disease other than FECD and cataract (exclusion of macular disease or edema by OCT)\n2. Iris synechiae, pupil diameter \\\u003C6 mm after dilatation, pseudoexfoliation syndrome, subluxated lens, previous history of ocular trauma\u002Fsurgery or inflammatory disease\n3. Subjective diurnal changes in visual acuity with worse visual acuity in the morning\n4. Corneal (epithelial) edema visible at slit lamp examination\n5. Preoperative anterior chamber depth below 2 mm\n6. Participation in other interventional trials parallel or within the last 4 weeks\n7. Systemic use of Alpha-1-Adrenozeptor-Antagonists, immunosuppressive therapy or chemotherapy\n8. Pregnant women and nursing mothers\n9. Persons with any kind of dependency on the principal investigator or employed by the sponsor or principal investigator\n10. Legally incapacitated persons\n11. Persons held in an institution by legal or official order",{"count":416,"type":21},120,[112],"The purpose of the study is to investigate whether there is a difference in BCVA in patients who receive one of the following two surgeries: intervention group (arm 1) cataract surgery alone and control group (arm 2) cataract surgery combined with removal of the diseased endothelial cells and the attached Descemet's membrane followed by transplantation of a healthy endothelial cell layer with attached Descemet's membrane (\"triple-DMEK\" group; comparator therapy).\n\nThe secondary objectives are to compare the two surgical methods with regard to other visual functions and optical as well as morphological differences, to safety, to quality of life, and to safety.",[420,421],"Cataract Surgery","Cataract and Fuchs Endothelial Corneal Dystrophy",[423,424,425,426,427],"Fuchs´ Endothelial Corneal Dystrophy Krachmer grade 3 and 4","nuclear cataract","Nuclear opalescence (NO) grades 2","Nuclear opalescence (NO) grades 3","Central corneal thickness","2025-02-19",{"date":430,"type":32},"2025-02-21",{"date":432,"type":32},"2025-01-24",{"date":434,"type":21},"2026-06",{"name":38,"class":39},4,{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":83,"sex":17,"minAge":443,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":457,"locationsCount":100},"100513742","hair-cortisol-as-marker-of-chronic-stress-in-preterm-and-term-fathers---fathair-study-100513742","NCT05969431","Hair Cortisol as Marker of Chronic Stress in Preterm and Term Fathers - Fathair-study","Inclusion Criteria:\n\n* Premature or mature infant (22 0\u002F7 to 42 0\u002F7 weeks of gestation)\n* For mature infants (37 0\u002F7 to 42 0\u002F7 weeks of gestation) undisturbed neonatal period\n* No severe malformations or genetic diseases of the newborn child\n* Sufficient knowledge of German of the father\n* written consent of the custodial parents\n\nExclusion Criteria:\n\n* adoptive or foster paternity\n* hair length below 3 cm at the posterior vertex region of the back of the father's head\n* endocrine disorders, especially of the adrenocortical system (e.g. Cushing syndrome, adrenal insufficiency)\n* taking steroidal medications or other drugs that affect the activity of the hypothalamic-pituitary-adrenocortical system\n* paternal psychological or severe physical illness","1 Day","7 Days",{"count":416,"type":21},"The goal of this observational study is to compare the paternal hair cortisol as a marker for chronic stress in prematurely born children to maturely born children.\n\nThe main questions it aims to answer are:\n\n* How differ the cortisol level between groups?\n* How change the cortisol level over time?\n* Are there secondary outcomes associated to the cortisol level of fathers? Participants will give a hair sample to analyse the cortisol level and fill out questionnaires at three time points. At six months of the infant's age, the investigators will also measure the paternal sensitivity.",[448,449,450],"Stress, Psychological","Father-Child Relations","Premature Birth","2024-11-24",{"date":453,"type":32},"2024-11-27",{"date":455,"type":32},"2024-10-01",{"date":405,"type":21},{"name":38,"class":39},{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":11,"sex":17,"minAge":465,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":100},"100554255","implement---model-project-for-quality-assured-exercise-therapy-for-cancer-patients-100554255","NCT06496711","IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients","IMPLEMENT - Model Project for the Cross-sector Implementation of a Comprehensive and Quality-assured Sports and Exercise Therapy for Cancer Patients","Inclusion Criteria:\n\n* Patients with cancer\n* Healthcare providers (e.g. Medical Doctors, physiotherapists, nurses, psychologists) involved in the treatment and\u002For counseling of cancer patients, including aftercare.\n\nExclusion Criteria (Cancer Patients):\n\n* Psychological and\u002For physical limitations that do not allow participation in quality-assured sports and exercise therapy (e.g. unstable cardiac arrhythmias)","5 Years",{"count":467,"type":21},600,[112],"IMPLEMENT aims to develop, test and establish a sustainable access structure for quality-assured oncological exercise therapy (qOET) in Germany as a model within the funding period of three years. This will be done in three phases:\n\nPhase 1: In the first step, a characterization of the existing implementation structures and the existing barriers and needs as well as the establishment of the cooperation with the most important actors in the care system will take place.\n\nPhase 2: In the subsequent implementation process, concrete measures are practically implemented in subprojects for specific target groups (children\u002Fadolescents, adults) and specific regions (rural, urban) as well as the digital solutions and interface management. With the help of a mixed-methods design, the barriers and facilitating factors of the implementation of area-wide qSBT will be investigated during the project and fed into a \"learning system\" for adaptation and improvement.\n\nPhase 3: The success of the measures to increase patient participation in qOET and the development of the structures as well as the barrier and facilitating factors for an effective implementation will be addressed in a before-after comparison through evaluation steps and an economic accompanying evaluation will be carried out.",[471],"Cancer",[473,474],"exercise therapy","Implementation","2024-08-21",{"date":285,"type":32},{"date":478,"type":32},"2023-09-01",{"date":480,"type":21},"2026-02-28",{"name":38,"class":39},{"id":483,"slug":484,"hasResults":11,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":490,"enrollmentInfo":491,"targetDuration":4,"studyType":22,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":496,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":100},"100426872","phase-2-pembrolizumab-in-combination-with-salvage-chemotherapy-for-first-relapsed-or-refractory-classical-hodgkin-lymphoma-100426872","NCT04838652","Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","Phase II Trial of Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","Pembro-CORE","Inclusion Criteria:\n\n* Histologically confirmed first relapse of cHL or primary refractory cHL\n\nExclusion Criteria:\n\n* Nodular lymphocyte-predominant Hodgkin lymphoma or composite lymphoma","65 Years",{"count":492,"type":21},29,[24],"The aim of this trial is to develop an effective and well-tolerated regimen for treatment of r\u002Fr cHL by introducing the anti-PD-1 antibody pembrolizumab and adding it to well-established chemotherapy regimens (ICE, DHAP). Synergistic effects of conventional agents with checkpoint inhibition may facilitate a highly effective therapy with limited toxicity, which might eventually substitute the very toxic high-dose chemotherapy (HDCT).",[350],{"date":285,"type":32},{"date":498,"type":32},"2024-03-05",{"date":500,"type":21},"2028-05",{"name":38,"class":39},{"id":503,"slug":504,"hasResults":11,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":519,"locationsCount":100},"100426811","phase-2-phase-ii-trial-of-individualized-immunotherapy-in-early-stage-unfavorable-classical-hodgkin-lymphoma-100426811","NCT04837859","Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma","INDIE","Inclusion Criteria:\n\n* Age 18-60 for the main trial cohort\n* Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort\n* First diagnosis of treatment-naïve cHL\n* Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):\n\n  1. large mediastinal mass\n  2. extranodal lesion(s)\n  3. elevated erythrocyte sedimentation rate\n  4. ≥ 3 nodal areas\n\n     Exclusion Criteria:\n* Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and\u002For central nervous system involvement of lymphoma",{"count":416,"type":21},[24],"The aim of the trial is to establish an individualized first-line treatment incorporating checkpoint inhibition for early-stage unfavorable cHL, which is effective and well tolerated.",[350],"2024-07-25",{"date":515,"type":32},"2024-07-26",{"date":517,"type":32},"2024-05-24",{"date":500,"type":21},{"name":38,"class":39},{"id":521,"slug":522,"hasResults":11,"nctId":523,"briefTitle":524,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":100},"100320299","ecmm-candida-registry---candireg-100320299","NCT03450005","ECMM Candida Registry - CandiReg","CandiReg","Inclusion Criteria:\n\n* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection with Candida species.\n* Hepatosplenic candidiasis with signs of disseminated Candida infection without culture, histological or microscopic evidence\n* Case control\n\nMatching procedure for controls:\n\nIn part, controls will be included at the same hospitals that include cases (i.e. each one control per case, both in the same hospital).\n\nControls will be matched by demographics, underlying diseases and risk factors as well as duration of hospitalization\n\nExclusion Criteria:\n\n\\- Colonization or other non-invasive infection, including superficial skin infections, candiduria without dissemination or Candida spp. in stool.",{"count":137,"type":21},"The objective of the European Confederation of Medical Mycology - ECMM Candida Registry (CandiReg) is to overcome the lack of knowledge on epidemiology, clinical course, and molecular characteristics of invasive infections due to invasive Candida infections and to function as a platform for future studies and in case of outbreaks.",[530],"Invasive Candidiases","2023-12-11",{"date":533,"type":32},"2023-12-12",{"date":535,"type":32},"2018-01-18",{"date":537,"type":21},"2026-12-31",{"name":38,"class":39},{"id":540,"slug":541,"hasResults":11,"nctId":542,"briefTitle":543,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":547,"conditions":548,"keywords":550,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":556,"completionDateStruct":558,"leadSponsor":560,"locationsCount":100},"100188646","fungiscope---a-global-emerging-fungal-infection-registry-100188646","NCT01731353","FungiScope - A Global Emerging Fungal Infection Registry","FungiScope","Inclusion Criteria:\n\n* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection\n\nExclusion Criteria:\n\n* Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci\n* Endemic fungal infection such as coccidioidomycosis or histoplasmosis\n* Colonisation or other non-invasive infection",{"count":85,"type":21},"The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.",[549],"Invasive Fungal Disease",[551,552],"invasive fungal infection","Web-based registry","2023-12-04",{"date":555,"type":32},"2023-12-05",{"date":557,"type":4},"2003-03",{"date":559,"type":21},"2026-12",{"name":38,"class":39},""]